Advanced Search
Wang Xiaoming, Shen Yuechun, Li Jun. Expression Level and Significance of CCL18 in Plasma of Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 694-697. DOI: 10.3971/j.issn.1000-8578.2012.06.020
Citation: Wang Xiaoming, Shen Yuechun, Li Jun. Expression Level and Significance of CCL18 in Plasma of Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 694-697. DOI: 10.3971/j.issn.1000-8578.2012.06.020

Expression Level and Significance of CCL18 in Plasma of Breast Cancer Patients

More Information
  • Received Date: October 16, 2011
  • Revised Date: December 25, 2011
  • Objective To investigate the expression level and significance of CCL18 in the plasma of breast cancer patients. Methods 20 cases with benign breast diseases and 88 cases with breast cancer were studied.In the 88 breast cancer patients 43 cases received neoadjuvant chemotherapy.The 43 cases of breast cancer patients' blood specimens were collected before and after neoadjuvant chemotherapy,while the others samples were collected before any treatments.36 healthy women were collected as controls.The level of CCL18 in plasms was detected by enzyme linked immunosorbent assay(ELISA). Results The level of CCL18 in the breast cancer patients′ plasma was significantly higher than that in healthy group (P<0.01),and benign disease group (P<0.01).The correlation between the level of CCL18 in the plasma and erestrogen receptor (ER) was negative(P=0.018).There was no correlation between the CCL18 level and the neoadjuvant chemotherapy (P=0.431). Conclusion CCL18 is a biomarker of breast cancer,and negative correlation to the expression of estrogen receptor (ER).CCL18 is not an independent predictor for neoadjuvant chemotherapy in breast cancer.
  • [1]
    Leung SY,Yuen ST,Chu KM,et al.Expression profiling identifies chemokine (C-C motif) ligand 18 asan independent prognostic indicator in gastric cancer[J].Gastroenterology,2004,127(2):457-69.
    [2]
    Schutyser E,Struyf S,Proost P,et al.Identification of biologically active chemokine isoformsfrom ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine inovarian carcinoma[J].J Biol Chem,2002,277(27):24584-93.
    [3]
    Mantovani A.The chemokine system:redundancy for robust outputs [J].Immunol Today,1999,20(6):254-7.
    [4]
    Busse D,Doughty RS,Arteaga CL.HER-2/neu (erbB-2) and the cell cycle [J].Semin Oncol,2000,27(6 Suppl 11):3-8.
    [5]
    Miglietta A,Cayalli R,Bocca C,et al.Cellular uptake and cytotoxicity of solid lipidnanospheres (SLN) incorporating doxorubicin or paclitaxel [J].Int J Pharm,2000,210(1-2):61-7.
    [6]
    Adema GJ,Hartgers F,Verstraten R,et al.A dendritic-cell-derived C-C chemokine thatpreferentially attracts naive T cells [J].Nature,1997,387 (6634):713-7.
    [7]
    Guan P,Burghes AH,Cunningham A,et al.Genomic organization and biological characterization ofthe novel human CC chemokine DC-CK-1/PARC/MIP-4/SCYA18 [J].Genomics,1999,56(3):296-302.
    [8]
    Tasaki Y,Fukuda S,Lio M,et al.Chemokine PARC gene (SCYA18) generated by fusion of two MIP-1alpha/LD78alpha-like genes[J].Genomics,1999,55(3):353-7.
    [9]
    Shilling V,Jenkins V,Morris R,et al.The effects of adjuvant chemotherapy on cognition inwomen with breast cancer--preliminary results of an observational longitudinal study [J].Breast,2005,14(2):142-50.
    [10]
    Budman DR.Dose and schedule as determinants of outcomes in chemotherapy for breast cancer[J].Semin Oncol,2004,31(6 Suppl 15):3-9.
    [11]
    Charfare H,Limongelli S,Purushotham AD,et al.Neoadjuvant chemotherapy in breast cancer [J].Br J Surg,2005,92(1):14-23.
    [12]
    Opdenakker G,Van den Steen PE,Laureys G,et al.Neutralizing antibodies in gene-defective hosts[J].Trends Immunol,2003,24(2):94-100.
    [13]
    Struyf S,Schutyser E,Gouwy M,et al.CCL18 8/CCL18 is a plasma CC chemokine with increasedlevels in childhood acute lymphoblastic leukemia [J].Am J Pathol,2003,163(5):2065-75.
    [14]
    Colcher D,Bird R,Roselli M,et al.In vivo tumor targeting of a recombinant single-chainantigen-binding protein[J].J Natl Cancer Inst,1990,82(14):1191-7.
    [15]
    Wu AM,Senter PD.Arming antibodies:Prospects and challenges for immunoconjugates [J].NatBiotechnol,2005,23 (9):1137-46.
    [16]
    Lin Y,Huang R,Chen L,et al.Identification of interleukin-8 as estrogen receptor-regulatedfactor involved in breast cancer invasion and angiogenesis by protein arrays [J].Int JCancer,2004,109(4):507-15.
    [17]
    Lazennec G,Bresson D,Lucas A,et al.ER beta inhibits proliferation and invasion of breastcancer cells [J].Endocrinology,2001,142(9):4120-30.
    [18]
    Cheng J,Lee EJ,Madison LD,et al.Expression of estrogen receptor beta in prostate carcinomacells inhibits invasion and proliferation and triggers apoptosis [J].FEBF Lett,2004,566(1-3):169-72.
    [19]
    Lazennec G.Estrogen receptor beta,a possible tumor suppressor involved in ovariancarcinogenesis [J].Cancer Lett,2006,231(2):151-7.
    [20]
    Ravdin PM,Chamness GC.The c-erbB-2 proto-oncogene as a prognostic and predictive marker inbreast cancer:a paradigm for the development of other macromolecular markers-a review [J].Gene,1995,159(1):19-27.
    [21]
    Petit T,Wilt M,Velten M,et al.Comparative value of tumour grade,hormonal receptors,Ki-67,HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated withneoadjuvant anthracycline-based chemotherapy [J].Eur J Cancer,2004,40(2):205-11.

Catalog

    Article views PDF downloads Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return